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Summary A case-control study was conducted in Los Angeles County, California, of 127 endometrial cancer
cases aged 45 years or less at diagnosis, to investigate the role of fertility, obesity and exogenous oestrogens in
the development of the disease in young women. Use of sequential oral contraceptive (SOCs) or oestrogen
replacement therapy (ERT) for .2 years was strongly associated with increased risk of endometrial cancer.
After excluding these cases, since the SOC or ERT use was probably the cause of their disease, we were left
with 110 case-control pairs for further study. Among these remaining case-control pairs increasing parity was
strongly associated with decreased risk (relative risk of 0.12 for women of parity 3 compared to nulliparous
women, P<0.001). Current weight was associated with increased risk (relative risk of 17.7 for women
weighing .190lbs compared to women weighing <130lbs, P<0.001). Combination oral contraceptive
(COC) use was associated with a decreased risk, which decreased with duration of COC use (relative risk of
-0.28 at 5 years of use, P<0.001), but the estimate of the protective effect was reduced and became
statistically non-significant when allowance was made for weight and parity. The protective effect of COC use
was only clearly evident in women who had less than 3 live-births and weighed less than 170lbs. These results
provide further support for the "unopposed" oestrogen hypothesis of the aetiology of endometrial cancer.
Users of combination oral contraceptives have been
reported to be at decreased risk of endometrial
cancer in 4 recent case-control studies (Kaufman et
al., 1980; Weiss & Sayvetz, 1980; Hulka et al., 1982;
Kelsey et al., 1982). It is not obvious how
combination oral contraceptive use may "interact"
with other endometrial cancer risk factors: in the
above studies the numbers of ever-users of
combination oral contraceptives were small, and the
possible modifying effects of other risk factors were
not (and probably could not be) discussed in any
detail.
We report here the results of a case-control study
of 127 endometrial cancer patients aged 45 years or
less at diagnosis. By restricting attention to these
young women we hoped to obtain a sufficient
number of oral contraceptive users that the possible
interaction with other risk factors could be
evaluated.
Methods
The cases were white women with microscopically
confirmed adenocarcinoma of the endometrium
(excluding carcinoma in situ) first diagnosed
between January 1972 and December 1979. Any
such woman, unless she had a Spanish surname and
was born outside the United States, was eligible for
inclusion if she was 45 years of age or less at
diagnosis with no prior malignancies, was still alive
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and in the opinion of her physician was able to be
interviewed, and was a resident of Los Angeles
County at the time of her diagnosis. The cases were
identified by the University of Southern California
Cancer Surveillance Program (CSP), the population
based cancer registry for Los Angeles County
(Mack, 1977).
The CSP identified 185 such cases; 36 of these
women refused to be interviewed. We obtained
completed questionnaires on 149 (81%).
We sought one individually-matched control for
each of these 149 cases. The control had.to be white
(excluding foreign-born if with a Spanish surname),
have a birth date within 5 years of her matched
case, have no prior malignancies, and have an
intact uterus on her "pseudo-diagnosis" date
(defined below). She also had to be at least as old at
interview as her matched case was at diagnosis.
The controls were obtained by a procedure that
defines a sequence of houses on specified
neighbourhood blocks in the area where the
matched case resided at the time of her diagnosis.
Our goal was to interview the first matching female
resident in the sequence. If no one was home at the
time of visit, we left an explanatory letter and made
3 further follow-up visits some days later. In 110
instances, the first appropriate person agreed to
participate. The second matched control cooperated
in 14 instances, the third match in 2 instances, and
the fourth match in 6 instances. For any patient, 80
housing units were visited before failure to secure a
matched control was conceded. We were unable to
locate a suitable match for 17 of the 149 cases. In
all, 132 matched neighbourhood controls were
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found and questionnaires completed. Five of the
132 sets were excluded from the analysis since the
type of oral contraceptive (i.e. sequential or
combination) used by one or other of the pair could
not be determined. Such oral contraceptive
information was lacking on 2 controls and on 3
cases, even after we contacted their physicians. This
left a total of 127 case-control pairs.
One of us (I.R.) conducted all interviews by
telephone. Information obtained included
reproductive, menstrual, contraceptive, and
gynaecological history, hormone and other drug
use, and family history of cancer, up to the date of
diagnosis of endometrial cancer. Each control was
given a "pseudo-diagnosis" date which was the date
on which she would have been the exact age her
matched case was at her diagnosis of endometrial
cancer. The diagnosis/pseudo-diagnosis date is
referred to throughout the text as the "diagnosis
date". The use of any drugs for the first time within
6 months of the diagnosis date was ignored.
The combination oral contraceptives commonly
used in the U.S. contain either mestranol or ethinyl
oestradiol as their oestrogenic component, and one
of the 5 gestagens-norethindrone, norethynodrel,
norethindrone acetate, ethynodiol diacetate or
norgestrel. The relative oestrogenic potencies of the
2 oestrogens is 1 and 2 respectively (Delforge &
Ferin, 1970), and the relative potencies of the 5
gestagens is 1, 1.09, 2, 15 and 30 respectively
(Greenblatt, 1967). A potency ratio (E/G ratio) may
be calculated (Mishell, 1979) for each preparation as
(oestrogen component in mcg x relative potency)
dividend by (gestagen component in mg x relative
potency). The E/G ratio of the commonly-used
preparations varies from 6.7 for Demulen to 175 for
Ovcon-35 (Mishell, 1979). Although women
frequently could not recall the precise oral
contraceptive formulation used (a woman who took
Ortho-Novum pills may not have remembered
whether it was Ortho-Novum 1/50 or Ortho-
Novum 1/80), the different preparations can be
separated into a high E/G ratio group (E/G ratio
over 45) and a low E/G ratio group such that more
precise recall information was not needed.
Multivariate regression methods for individually
matched case-control studies were used for
statistical analysis (Breslow et al., 1978; Holford et
al., 1978; Smith et al., 1981; Thomas, 1981). The
odds ratios estimated from such analyses closely
approximate the related relative risks and the latter
term is used in the text for clarity of presentation.
Results
Eleven of the patients were aged < 30 years at
diagnosis, 49 were aged 31-40, and 67 were aged
41-45. The socio-economic class of the patients and
their individually-matched controls were very
similar, as would be expected from the method of
choosing controls by neighbourhood.
The relative risk (RR) for endometrial cancer was
increased by long-term use of sequential oral
contraceptives (SOCs) (Table I): 10 women had used
SOCs for .2 years, 9 of these women were cases.
Five of the 9 cases with long-term SOC use had
used C-Quens, 4 had used Oracon, and 1 each had
used Norquens and Ortho-Novum SQ. As expected,
oestrogen replacement therapy (ERT) was
associated with increased risk (Table I), although
the result was not statistically significant. One may
conclude from these results and other published
series (Lyon, 1975; Smith et al., 1975; Ziel et al.,
1975; Mack et al., 1976; McDonald et al., 1977;
Kelsey et al., 1982) that long-term (.2 years) SOC
or ERT use was the cause of the endometrial cancer
in most of the long-term SOC or ERT users. For
this reason we excluded from all further analyses
those case-control pairs in which either case or
control used SOC or ERT for >2 years, leaving
110 case-control pairs (in 1 case-control pair both
case and control had used SOC for >2 years).
Table I Relative risks for two known endometrial cancer
risk factors
Factor Cases Controls RR* Pt
Sequential 0 116 121 1.00 0.0071
O.C. (years) <2 2 5 0.40
2+ 9 1 4.60§
Oestrogen 0 112 118 1.00 0.21t
replacement <2 9 7 1.38
therapy 2+ 6 2 3.13
(years)
*Matched relative risk.
tI-sided statistical significance level.
tFor linear trend in logistic model to actual number of
years of use.
§Estimated odds ratio at 3 years. Actual "matched"
observed odds ratio is infinity, as the single control was
matched to a case who took sequentials for more than 2
years.
The RR for endometrial cancer was significantly
decreased by increasing numbers of full-term (.28
weeks) pregnancies (FTPs) (Table II): a woman who
had had .4 FTPs had only 6% the risk of a
nulliparous woman. Incomplete pregnancies
(spontaneous and induced abortions) were
associated with a slight decrease in risk (data not
shown) 5.6 incomplete pregnancies was estimatedENDOMETRIAL CANCER IN YOUNG WOMEN 751
Table II Relative risks for various possible endometrial
cancer risk factors
Factor Cases Controls RR* Pt
Full-term 0 34 13 1.00 <0.001T
pregnancies 1 19 10 0.54
2 32 31 0.22
3 16 27 0.12
4+ 9 29 0.06
Combination, 0 67 50 1.00 <0.001§
O.C. (years) <2 23 22 0.75
2- 12 11 0.79
4- 4 9 0.28
6+ 4 18 0.14
Current -129 27 51 1.00 <0.001¶
weight 130- 28 38 1.45
(lbs) 150- 11 9 1.95
170- 13 6 9.60
190+ 31 6 17.70
Infertilityll No 66 91 1.00 <0.001
Yes 44 19 3.50
Amenorrhea** No 92 105 1.00 0.001
Yes 18 5 5.33
*Matched relative risk.
tl-sided statistical significance level.
$For linear trend in logistic model to actual number of
live-births.
§For linear trend in logistic model to actual number of
years of use.
¶For linear trend in logistic model to actual weight.
IIUnable to get pregnant for . 3 years.
**Amenorrhea "requiring" visit to physician.
as equivalent to 1 FTP in terms of risk reduction
but this decrease was not statistically significant (1-
sided P=0.31) and we do not consider incomplete
pregnancies further in this analysis. Age at first
FTP was not associated with any change in risk
when considered jointly with numbers of FTPs (1-
sided P=0.49). Similarly age at last FTP was not
associated with any change in risk when considered
jointly with numbers of FTPs (1-sided P=0.20).
The RRs associated with numbers of FTPs were
not significantly affected by age at first FTP or age
at last FTP.
The RR for endometrial cancer decreased steadily
with increasing use of combination oral
contraceptives (COCs): a woman with .6 years of
COC use had 14% the risk of a woman who never
used COCs (Table II). Recent COC use (i.e. use
within 1 year of the diagnosis date) was positively
associated with duration of COC use. However,
there was no effect of recency of COC use over and
above the effect explicable by this association with
duration of COC use. Table III shows that use of
COCs with either "High" or "Low" oestrogen to
Table III Unmatched relative risks (RR) for com-
bination O.C. (COC) use categorised by oestrogen to
gestagen (E/G) ratio*
Low E/G ratio COC use
(years)
0 <2 2- 6+
0 Cases 79 10 4 1
Controls 59 9 6 9
RR 1.00 0.83 0.50 0.08
High <2 Cases 5 1 1 1
E/G Controls 8 2 2 0
ratio RR 0.47 0.37 0.37 0.00
COC 2- Cases 4 3 0 0
use Controls 7 0 2 0
(years) RR 0.43 0.00 0.00
6+ Cases 1 0 0 0
Controls 5 1 0 0
RR 0.15 0.00
*See Methods section for definition ofE/G ratio.
gestagen ratios was associated with a reduced risk
of endometrial cancer, and the effect was not clearly
dependent on the E/G ratio at least over the range
defined by our crude division into "High" and
"Low".
The RR for endometrial cancer was significantly
increased by increasing "current" weight (i.e. weight
recorded 1 year prior to diagnosis): a woman who
weighed .190lbs had almost 18 times the risk of a
woman who weighed < 130lbs. (Table II).
Quetelet's index (weight/height2) was also
significantly positively related to the risk of
endometrial cancer. In this data, weight and
Quetelet's index were very highly correlated, so that
neither relationship with endometrial cancer risk
was significant after allowance was made for the
other, and Quetelet's index was slightly less
discriminatory than weight alone. We have
therefore presented only the results for weight.
Weight at age 18 was strongly associated with
risk of endometrial cancer (see second last line in
Table IV). The effect could, however, be almost
completely "explained" by current weight (see last
line in Table IV), so that weight at age 18 does not
add much further information if current weight is
known. The RR associated with current weight was
only slightly modified by knowledge of weight at
age 18. Five cases but no controls had been
diagnosed as having diabetes. The cases weighed
185, 195, 200, 225 and 250lbs so that the increased
risk 'cannot be distinguished from that due to
weight alone.
Long-term infertility, defined as a "recognised"
inability to get pregnant for . 3 years, was752 B. E. HENDERSON et al.
Table IV Unmatched relative risks (RR) for weight at
age 18 stratified by current weight
Weight at age 18
Current
weight -129 130- 170+
-129 Cases 23 4 0
Controls 48 3 0
RR 1.00 2.78
130- Cases 22 16 1
Controls 28 18 1
RR 1.00 1.13 1.27
170+ Cases 14 24 6
Controls 3 8 1
RR 1.00 0.64 1.29
All Cases 59 44 7
Controls 79 29 2
RR 1.00 2.10 4.75
RR adjusted 1.00 1.17 1.28
for current weight
associated with a 3.5-fold increased risk of
endometrial cancer (Table II). Infertility of shorter
duration was not associated with an increased risk;
and there was no further increase in risk with
recognised infertility of longer duration.
Amenorrhea "requiring" a physician visit was
associated with a 5.3-fold increased risk of
endometrial cancer (Table II).
Table V shows the maximum likelihood estimates
of the logistic parameters (log RRs) for each of the
5 risk factors in Table II fitted singly. All were
statistically significant. The Table also shows the
estimated parameters and associated significance
levels when the 5 factors were fitted together. Only
FTPs, current weight and amenorrhea remained
statistically significant at the conventional 1-sided
5% level.
Table V Logistic analysis of various possible endometrial
cancer risk factors
Fitted singly* Fitted together*t
Factor F RR P F RR P
Full-term -0.61 0.54 <0.001 -0.51 0.61 <0.001
pregnancies
Com- -0.17 0.85 <0.001 -0.058 0.94 0.17
bination
O.C.
(1 year increments)
Current 0.23 1.26 <0.001 0.17 1.19 <0.001
weight
(1Olb increments)
Infertility 1.25 3.50 <0.001 0.71 2.02 0.07
Amenorrhea 1.67 5.33 <0.001 1.97 7.19 0.005
*1-sided statistical significance level.
tAfter fitting other 4 factors.
The matched RRs associated with current weight
. 170lbs were very large, and since it was possible
that this extreme level of risk was dominating the
multivariate analysis and making it difficult to
evaluate the effects of other potential risk factors,
we looked at the other risk factors stratified by
weight (Table VI).
Table VI Unmatched relative risks (RR) for various
possible endometrial cancer risk factors stratified by
current weight
Current
weight Full-term pregnancies
-169 Cases
Controls
RR
170+ Cases
Controls
RR
0
23
12
1.00
11
1.00
7
9
0.41
12
1
1.09
2
17
30
0.30
15
1
1.36
3
11
21
0.27
5
6
0.08
4+
8
26
0.16
1
3
0.03
Combination O.C. (years)
-169 Cases
Controls
RR
170+ Cases
Controls
RR
-169 Cases
Controls
RR
170+ Cases
Controls
RR
0
41
41
1.00
26
9
1.00
<2
13
21
0.62
10
1
3.46
Infertility
N Y
46 20
80 18
1.00 1.93
20 24
11 1
1.00 13.20
2-
7
10
0.70
5
1
1.73
4- 6+
2 3
9 17
0.22 0.18
2 1
0 1
1.04
Amenorrhea
N Y
64 2
93 5
1.00 0.58
28 16
12 0
1.00 oo
The protective effect of increasing numbers of
FTPs was evident both in the "obese" women
(current weight . 170lbs) and in the "non-obese"
women. The protective effect of increasing COC use
was evident only in the non-obese women.
Infertility was associated with a larger increase in
risk in obese women (unmatched RR=13.20), but
was also evident in the non-obese women
(unmatched RR = 1.93). The increased risk
associated with amenorrhea was also greatly
elevated in obese women, and there was no
increased risk in the non-obese.
Table VII shows the matched RRs for the 5 risk
factors of interest for the 63 case-control pairs in
which both members weighed <170 lbs. The RRsENDOMETRIAL CANCER IN YOUNG WOMEN 753
Table VII Relative risks for various possible endometrial
cancer risk factors: 63 case-control pairs with weight
< 170lbs
Factor Cases Controls RR* Pt
Full-term 0 21 6 1.00 0.0011
pregnancies 1 7 7 0.13
2 16 17 0.15
3 11 14 0.12
4+ 8 19 0.05
Combination 0 39 27 1.00 0.01§
O.C. (years) <2 13 14 0.68
2- 6 6 0.89
4- 2 6 0.33
6+ 3 10 0.20
Current -129 27 33 1.00 0.16¶
weight (lbs) 130- 26 23 1.30
150- 169 10 7 1.57
Infertility No 43 52 1.00 0.03
Yes 20 11 2.29
Amenorrhea No 61 63 1.00 0.25
Yes 2 0 00
*Matched relative risk.
ti-sided statistical significance level.
$For linear trend in logistic model to actual number of
live-births.
§For linear trend in logistic model to actual number of
years of use.
TFor linear trend in logistic model to actual weight.
are all consistent with those shown for all women in
Table II. Table VIII shows the multivariate analysis
for the 3 statistically significant risk factors (FTPs,
COC and infertility): only numbers of FTPs
remained statistically significant when the factors
were considered jointly. One FTP was the
equivalent of -5 years of COC use (0.41/0.080).
The reason for the disappearance of infertility as a
risk factor was that 50% (10/20) of the infertile cases
were nulliparous, while only 18% (2/11) of such
controls were nulliparous.
Table VIII Logistic analysis of various possible
endometrial cancer risk factors: 63 case-control pairs with
weight <170lbs
Fitted singly Fitted together
Factor 6 RR P* RR P*t
Full-term -0.46 0.63 0.001 -0.41 0.66 0.001
pregnancies
Com- -0.13 0.88 0.01 -0.080 0.92 0.10
bination
O.C. (1 year
increments)
Infertility 0.83 2.29 0.03 0.08 1.08 0.44
*I-sided statistical significance level.
tAfter fitting other 2 factors.
There was no effect of age at menarche or age at
establishment of regular cycles (or duration of time
from menarche to establishment of regular cycles)
on the risk of endometrial cancer.
There was no evidence of any increased risk
associated with intra-uterine contraceptive devices.
The stage of the endometrial cancer at diagnosis
could be determined fromp the CSP records in
72/110 cases. Forty-three had strictly localised
disease (local) and 29 had tumour extension at least
into the distal two thirds of the myometrium
(invasive). The above risk factors were clearly
evident for both groups, but the number of invasive
cases was not sufficient to be sure that the
magnitudes of the effects were the same.
One case and 1 control reported that they had
been diagnosed with polycystic ovarian disease
(PCO) before the diagnosis date. Three additional
cases were found to have PCO at the time of
diagnosis. The PCO cases weighed 130, 175, 200
and 220lbs, and all were infertile.
Five cases, but only 1 control, reported
endometrial cancer in a first degree relative (cases-
2 mothers and 3 sisters; controls-1 mother). An
additional 5 cases and 1 control reported cancer of
the cervix in a first degree relative; some of these
may actually have been carcinomas of the
endometrium. Breast cancer in a first degree relative
was reported by 4 cases and 7 controls.
Discussion
The present case-control study of young white
women in the Los Angeles area shows clearly that
long-term use of sequential oral contraceptives
(SOCs) increases the risk of endometrial cancer.
SOCs were removed from sale in 1976 because of
case reports of endometrial cancer in SOC users
(Lyon, 1975), and data suggesting that among
young endometrial cancer cases who took oral
contraceptives the proportion taking SOCs was
disproportionately high (Silverberg & Makowski,
1975). The oestrogenic component of Oracon is
0.1 mg ethinyl oestradiol while the oestrogenic
components of the other SOCs is 0.08mg
mestranol; mestranol has only half the oestrogenic
potency of ethinyl oestradiol (Greenblatt, 1960).
This suggests that Oracon may be more strongly
related to endometrial cancer. In the study of Weiss
& Sayvetz (1980) the increased risk of SOCs
appeared to be restricted to Oracon users, but we
found no evidence of an especially raised risk with
this formulation (SOC users: Oracon-6 cases and 3
controls; C-Quens-5 cases and 3 controls; other
formulations-2 cases and 1 control). We do not
have enough data to settle this question. Only 3/9754 B. E. HENDERSON et al.
long-term SOC cases used SOCs within 6 months
of their date of diagnosis, and it therefore appears
that the increased risk is not restricted to current
users.
Although the increased risk associated with
oestrogen replacement therapy (ERT) was not
statistically significant, the magnitude of the
observed risk was compatible with that found in
many studies of post-menopausal endometrial
cancer cases (Smith et al., 1975; Ziel et al., 1975;
Mack et al., 1976; McDonald et al., 1977; Kelsey et
al., 1982).
We eliminated from all further analyses the 17
case-control pairs in which either the case or the
control had used SOCs or ERT for .2 years. We
did this in order to simplify the presentation and so
that we did not need to build these 2 variables into
all calculations of relative risks for other factors.
The usual straightforward "adjustment" using
logistic methods assumes that the relative risks of
different factors is multiplicative and we saw no
reason to assume this for the sake of retaining these
17 pairs.
The present study provides clear evidence that
the risk of endometrial cancer in young women is
markedly increased by obesity. It is well known that
obesity is a major risk factor for endometrial cancer
in post-menopausal women (Damon, 1960; Wynder
et al., 1966; Elwood et al., 1977; Kelsey et al., 1982;
La Vecchia et al., 1982), and case reports have
suggested that young endometrial cancer cases tend
to be very obese (Sommers et al., 1949; Dockerty et
al., 1951; Peterson, 1968). In our population 50%
(55/110) of the cases weighed 2150lbs, and the
associated attributable risk percent (ARP) is 38%,
i.e. 38% of the current cases of endometrial cancer
in Los Angeles County in young women are
attributable to obesity, defined as weighing
. 150lbs.
Obesity is thus now clearly established as an
extremely important (and presumably preventable)
cause ofendometrial cancer both in pre-menopausal
and post-menopausal women. Table VI shows that
if the obesity is associated with infertility or
amenorrhea the risk of endometrial cancer is
particularly high.
This study shows that the risk of endometrial
cancer in young women is reduced considerably by
increasing numbers of FTPs. This is consistent with
the results of studies of older mainly post-
menopausal women (Damon, 1960; Wynder et al.,
1966; Elwood et al., 1977; Kelsey et al., 1982; La
Vecchia et al., 1982). Incomplete pregnancies also
appear to be protective. The extent of protection
afforded by an incomplete pregnancy relative to
that afforded by a FTP is roughly in proportion to
the length of the pregnancy. The decreased risk
associated with FTPs was not due to any
relationship between weight and numbers of FTPs.
The results shown in Tables II and VII suggest a
larger protective effect from first than from
subsequent pregnancies. Although analysis showed
that this effect was not statistically significant, such
an effect should be looked for in future studies.
Although the current study has only 1 less
endometrial cancer case who had ever used COCs
than all other studies combined (Kaufman et al.,
1980; Weiss & Sayvetz, 1980; Hulka et al., 1982;
Kelsey et al., 1982), we still have too little data to
be able to accurately estimate the protective effect
of COC use or to confidently delineate the group of
women for whom it is protective. We saw in Table
VI that COC use does not appear to be protective
in obese women, and the decreased risk in non-
obese women is not statistically significant when
considered together with numbers of FTPs.
Inspection of the data (not shown) suggests that the
reason for the latter reduction in effect is that COC
use does not appear to be protective in women with
>3 FTPs. Further study of large numbers of young
endometrial cancer cases is needed to settle these
issues.
The greatly increased risk associated with obesity
in post-menopausal women has been interpreted in
"excess" oestrogen terms by a number of authors
(Siiteri, 1978; Nisker et al., 1980; Henderson et al.,
1982). Plasma oestrogen in the post-menopausal
woman is largely derived by extra-glandular
conversion of androstenedione to oestrone, and the
rate of this aromatization increases with body
weight since adipose tissue is particularly rich in the
necessary enzymes (Siiteri & MacDonald, 1973).
Oestradiol is then derived from peripheral
conversion of oestrone (Vermeulen & Verdonck,
1978). The bio-availability of oestradiol may be
related to the concentration of sex-hormone-binding
globulin (SHBG) in the serum, and recent results
show that the SHBG concentration is lower in
obese women (Nisker et al., 1980). Thus, obese
women not only have greater concentrations of
circulating oestrogens, but the oestradiol may be
more available to oestrogen-responsive tissue.
Progesterone and other gestagens have profound
effects on the endometrium and are therapeutically
useful in treating both endometrial hyperplasia and
carcinoma. Gestagens increase the activity of the
dehydrogenase that converts oestradiol to the
biologically less active oestrone (Tseng & Gurpide,
1976); and gestagens decrease the concentration of
oestradiol receptors (Hsueh et al., 1975). Maximum
mitotic activity in the endometrium occurs in the
follicular phase of the cycle, and gestagens cause
differentiation of the endometrial cells to a secretory
state (Novak & Woodruff, 1979).ENDOMETRIAL CANCER IN YOUNG WOMEN 755
The "unopposed oestrogen hypothesis" for
endometrial cancer joins these two factors together
(Siiteri, 1978; Nisker et al., 1980; Henderson et al.,
1982). Our results showing the especially increased
rate of endometrial cancer in obese women with
amenorrhea provide very strong support for this
hypothesis. Increased fertility may protect against
endometrial cancer directly-the state of the
endometrium during pregnancy being very similar
to its state during the luteal phase of the cycle with
little mitotic activity. Part of the protection from
increased parity may, however, be indirect-high
parity may imply a low frequency of anovular
cycles in which little or no progesterone is
produced.
Protection from long-term COC use also
supports the unopposed oestrogen hypothesis-the
gestagen component of COCs normally being
sufficiently potent to prevent proliferation of the
endometrium (Anderson, 1979). The dose of
gestagen may, however, not be sufficiently strong to
inhibit endometrial proliferation in very obese
women; this would explain our failure to find a
protective effect of COC use in such women. We
have not been able to find information about the
state of the endometrium in very obese women on
COCs.
Although there was no overall effect of age at
menarche or duration of time from menarche to
establishment of regular cycles on endometrial
cancer risk, these negative results appeared to be
due to essentially contradictory results in different
weight categories of cases. Relative to controls the
obese cases tended to have early menarche and long
duration to establishment of regular cycles, while
the non-obese cases tended to have late menarche
and short duration to establishment of regular
cycles. None of these results were, however,
statistically significant and a large study will be
neede to shed light on this question.
We wish to thank all the patients and controls who
participated in this study-their willingness to answer
both our initial and follow-up questions is deeply
appreciated.
We are most grateful to Mrs. J. Howland for superb
secretarial assistance throughout this study.
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